6.3 Systemic, Neuraxial & Regional Analgesia in Labor

Systemic Pharmacologic Analgesia

1. Inhaled Nitrous Oxide

Nitrous oxide is an inhaled analgesic gas administered as a fixed, premixed formulation of 50% nitrous oxide (N2O) and 50% oxygen (O2).

• Mechanism of Action: Stimulates endogenous opioid release, activates GABA-A receptors, and inhibits NMDA receptors in the central nervous system, creating analgesia, mild euphoria, and dissociation without motor blockade.
• Administration Technique: Strictly client-controlled and self-administered. The laboring woman holds a handheld mask equipped with a one-way demand valve and a gas scavenger system. She begins inhaling deeply approximately 30 seconds prior to an anticipated contraction, ensuring peak drug absorption aligns with the peak intensity of the contraction.
• Pharmacokinetics: Rapid alveolar uptake with onset of action within 30 to 50 seconds; rapid pulmonary clearance within minutes of mask removal.
• Safety & Benefits: Does not depress myometrial contractility, does not alter baseline FHR or variability, and does not cause neonatal respiratory depression. The woman retains protective airway reflexes and full mobility.
• Contraindications: Inability of the patient to hold the mask independently (a support person or clinician must never hold the mask), hemodynamic instability, impaired consciousness, acute alcohol or sedative intoxication, severe pneumothorax, bowel obstruction, middle ear surgery, or known vitamin B12 deficiency.

2. Systemic Intravenous Opioids

Critical Safety Rules for Parenteral Opioids

1. Ceiling Effect of Mixed Agonist-Antagonists: Butorphanol and nalbuphine exhibit a ceiling effect, meaning higher doses do not cause progressive respiratory depression; however, they also exhibit a ceiling on analgesic efficacy.
2. The Opioid-Dependent Absolute Contraindication: Administering butorphanol or nalbuphine to an individual with opioid use disorder or someone maintained on methadone or buprenorphine is strictly contraindicated. Because these agents possess high-affinity partial mu-antagonist activity, they will rapidly displace pure mu-agonists from central receptors, precipitating immediate, severe acute opioid withdrawal (acute maternal hypertension, tachycardia, violent diaphoresis, severe abdominal cramping, and acute fetal distress).
3. Timing Relative to Delivery: Maternal IV opioids cross the placenta via passive diffusion. If administered within 1 to 2 hours of birth, fetal drug levels peak just as the umbilical cord is clamped, leading to neonatal respiratory depression, decreased muscle tone, impaired suckling, and hypothermia.
4. Neonatal Resuscitation & Naloxone Caution: In the event of opioid-induced neonatal respiratory depression, the primary intervention per Neonatal Resuscitation Program (NRP) guidelines is effective positive-pressure ventilation (PPV) and airway management. Naloxone (Narcan) is not recommended as part of initial delivery room resuscitation, and is strictly contraindicated in neonates born to opioid-dependent individuals, as it can trigger life-threatening neonatal seizures and acute cardiopulmonary collapse.

---

Neuraxial Analgesia: Epidural, CSE & Spinal

Neuraxial techniques provide the most effective pain relief available in modern obstetrics:

• Epidural Analgesia: Continuous infusion or Patient-Controlled Epidural Analgesia (PCEA) of a dilute local anesthetic (e.g., bupivacaine 0.0625%–0.125% or ropivacaine) combined with a lipid-soluble opioid (e.g., fentanyl 2 mcg/mL) into the lumbar epidural space (typically at L2–L3 or L3–L4).
• Combined Spinal-Epidural (CSE): Combines an immediate intrathecal "single-shot" injection of a low-dose local anesthetic and opioid into the subarachnoid space (providing instant, dense pain relief within 2 to 5 minutes) with the placement of an indwelling epidural catheter for ongoing maintenance.
• Pre-Procedure Evaluation:
  • Platelet Count: Platelets must be verified. While individual clinical scenarios vary, a platelet count ≥ 70,000 to 100,000/μL with normal coagulation parameters is generally required to avoid the catastrophic risk of an epidural hematoma causing spinal cord compression.
  • Intravascular Pre-Hydration: Administer a rapid crystalloid infusion of 500 to 1,000 mL Lactated Ringer's to expand intravascular volume.

Procedural Side Effects & Complications

Exam Watchout — Epidural Blood Patch: The definitive gold-standard treatment for persistent, severe post-dural puncture headache (PDPH) failing conservative therapy is an autologous epidural blood patch. Under sterile technique, 15 to 20 mL of the patient's own venous blood is drawn and injected directly into the epidural space at or adjacent to the prior dural puncture site. The coagulating blood forms a mechanical gelatinous plug that halts further CSF leakage, providing immediate relief in >90% of cases.

---

Local & Regional Nerve Blocks

1. Pudendal Nerve Block

The pudendal block is a highly effective regional nerve block utilized during late second stage, operative vaginal delivery (vacuum or forceps), or extensive perineal and vaginal laceration repair (third- or fourth-degree lacerations).

• Neuroanatomy: The pudendal nerve originates from the ventral rami of the second, third, and fourth sacral nerves (S2, S3, S4). It exits the pelvis through the greater sciatic foramen, crosses behind the ischial spine and sacrospinous ligament, and re-enters the pelvis through the lesser sciatic notch, traveling along the lateral wall of the ischiorectal fossa within Alcock's canal.
• Sensory Distribution: Provides dense somatic sensory anesthesia to the lower vagina, labia majora and minora, perineal body, and perianal region. Importantly, it does not eliminate uterine contraction pain (T10–L1) and does not cause motor blockade of maternal abdominal pushing muscles.
• Anatomical Landmarks & Technique:
  1. The CNM palpates the maternal ischial spine and the adjacent sacrospinous ligament transvaginally with the index and middle fingers.
  2. A specialized needle guide (the Iowa trumpet) is positioned through the vagina directly against the sacrospinous ligament, approximately 1 cm medial and posterior to the ischial spine tip.
  3. A long 20- or 22-gauge needle is advanced through the guide, piercing the sacrospinous ligament until a subtle "pop" or loss of resistance is felt.
  4. Mandatory Aspiration: The clinician must aspirate vigorously prior to injection to ensure the needle tip has not entered the internal pudendal artery or vein, which run immediately adjacent to the nerve.
  5. Inject 5 to 10 mL of 1% lidocaine (or 2-chloroprocaine) without epinephrine into the space behind the ligament. The procedure is repeated on the contralateral side for a bilateral block.

2. Local Perineal Infiltration

Direct infiltration of local anesthetic into the tissues of the posterior fourchette and perineal body prior to performing an indicated episiotomy or repairing first- and second-degree perineal lacerations.

• Agent: 1% or 2% lidocaine without epinephrine (maximum safe dose: 4.5 mg/kg or up to 300 mg, equivalent to 30 mL of 1% lidocaine).
• Technique: Insert the needle into the apex of the mucosal tear or fourchette, aspirate to rule out intravascular placement, and inject a fan-shaped field while slowly withdrawing the needle.